What Are SDTM Supplemental Qualifiers?
A detailed look at data that exists out with SDTM variables, known as SDTM supplemental…
CertaraSeptember 16, 2024
From Development to Patient Impact: Biohaven’s Nurtec™ Success Story
To learn more about Biohaven's success story, read our case study. Read the case study
CertaraSeptember 13, 2024
4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
CertaraSeptember 12, 2024
Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report
Check out this article in Fierce Pharma to learn how Certara's US Market Access team…
CertaraSeptember 11, 2024
Certara Strategic Early Development Solutions
A comprehensive guide to optimizing early development strategies.
CertaraSeptember 9, 2024
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)
Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…
CertaraSeptember 9, 2024
Optimizing Avidity of Bispecific Drugs
Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…
CertaraSeptember 9, 2024
